<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838342</url>
  </required_header>
  <id_info>
    <org_study_id>API/2015/61</org_study_id>
    <nct_id>NCT02838342</nct_id>
  </id_info>
  <brief_title>Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors</brief_title>
  <acronym>EPICentro</acronym>
  <official_title>Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <brief_summary>
    <textblock>
      This study will evaluate the potential immunomodulatory synergy of the association of
      metronomic cyclophosphamide (CMC) and interferon-alpha (IFN-alpha).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of patients with an immune response defined as &quot;Tregs lymphocytes decrease ≥ 20% in blood by the flow cytometry technique&quot;</measure>
    <time_frame>at 3 months of the association CMC and Interferon-alpha</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Metronomic cyclophosphamide and interferon-alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronomic cyclophosphamide</intervention_name>
    <description>50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance</description>
    <arm_group_label>Metronomic cyclophosphamide and interferon-alpha</arm_group_label>
    <other_name>CMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha</intervention_name>
    <description>3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3</description>
    <arm_group_label>Metronomic cyclophosphamide and interferon-alpha</arm_group_label>
    <other_name>IFN-alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  performance status ECOG-WHO ≤ 1

          -  histologically proved neuroendocrine tumor with Ki67 &lt; or = 10%, metastatic or locally
             advanced without surgery possibility

          -  at least one measurable lesion based on RECIST criteria version 1.1

          -  signed written informed consent

        Exclusion Criteria:

          -  previous treatment with interferon or cyclophosphamide

          -  treatment by immunosuppressive drugs

          -  diabetes complicated by coronary artery disease or vasculopathy

          -  severe respiratory failure, chronic respiratory failure, COPD

          -  history of severe heart failure

          -  severe renal or hepatic impairment

          -  diabetes complicated with coronary artery disease or vasculopathy

          -  alcoholism unweaned

          -  uncontrolled epilepsy and/or achievement of the central nervous system functions

          -  history of severe depressive syndrome

          -  presence or history of severe psychiatric condition, particularly severe depression,
             suicidal thoughts or attempted suicide

          -  decompensated liver cirrhosis

          -  severe myelosuppression

          -  psoriasis and sarcoidosis

          -  active disease condition or uncontrolled infection

          -  association with the yellow fever vaccine

          -  association with phenytoin in prophylaxis

          -  hypersensitivity against interferon or cyclophosphamide

          -  prior history of other malignancy except for: basal cell carcinoma of the skin,
             cervical intra-epithelial neoplasia and other cancer curatively treated with no
             evidence of disease for at least 3 years

          -  pregnancy, breast-feeding or absence of adequate contraception for fertile patients

          -  patients under guardianship, curatorship or under the protection of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefano KIM, Dr</last_name>
    <email>stefanokim@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe BORG, Pr</last_name>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano KIM, Dr</last_name>
      <email>stefanokim@me.com</email>
    </contact>
    <investigator>
      <last_name>Stefano KIM, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano KIM, Dr</last_name>
      <email>stefanokim@me.com</email>
    </contact>
    <investigator>
      <last_name>Stefano KIM, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

